Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 1.53 billion

CAGR (2024-2029)

4.77%

Fastest Growing Segment

Intracorporeal Lithotripsy

Largest Market

North America

 

Market Overview

Global Urolithiasis Management Devices Market was valued at USD 1.53 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.77% through 2029. Due to various factors, there is a growing demand for urolithiasis management devices in the market. One significant contributor to this demand is the increasing global prevalence of urolithiasis. According to data from the European Association of Urology, the occurrence of urinary stones varies from 1% to 20%. Developed nations like Canada, Sweden, and the United States exhibit a notably higher prevalence of renal stones, exceeding 10%. A 2021 report from the British Association of Urological Surgeons confirms the commonality of kidney stones, with an 8% likelihood of developing in patients undergoing a CT scan. The incidence of kidney stones has been on a continuous rise since the early 20th century. Furthermore, it is estimated that 9% of individuals will experience symptoms related to stone formation at some point in their lifetime.

Key Market Drivers

Increasing Prevalence of Urolithiasis

Urolithiasis, commonly known as kidney stones, has emerged as a prevalent and escalating health concern, impacting millions of individuals worldwide. As the incidence of this painful condition continues to rise, so does the demand for cutting-edge urolithiasis management devices.

Urolithiasis is characterized by the formation of solid mineral masses within the urinary tract, often leading to intense pain and discomfort for those affected. This condition affects people of all ages and backgrounds, with the potential to significantly diminish their quality of life. According to data from medical organizations such as the European Association of Urology, the global prevalence of kidney stones ranges from 1% to 20%. Some developed nations, including Canada, Sweden, and the United States, have even reported rates surpassing 10%.

The foremost catalyst behind the surging demand for urolithiasis management devices is the sheer prevalence of kidney stones. As the number of individuals suffering from urolithiasis continues to grow, there is an urgent need for effective and efficient management tools. Patients and healthcare providers alike are seeking solutions that can alleviate the pain and complications associated with kidney stones.

The healthcare industry has witnessed remarkable advancements in the field of urology. These innovations have given rise to an array of sophisticated urolithiasis management devices that offer minimally invasive and precise methods for stone removal. Technologies such as laser lithotripters and advanced endoscopic tools have revolutionized treatment options, attracting both patients and healthcare professionals.

With increased access to information and healthcare education, patients are more informed about urolithiasis. This empowerment enables them to make informed decisions about their treatment. Patients are increasingly seeking out the latest and most effective urolithiasis management devices that can provide quicker recovery times and reduce discomfort during the treatment process.

The growth in urolithiasis cases has not gone unnoticed by the investment community. As the demand for urolithiasis management devices continues to rise, it presents an appealing investment opportunity for medical device manufacturers and healthcare technology companies. This, in turn, fuels research and development efforts aimed at creating even more innovative and effective devices for managing urolithiasis.

Public health initiatives and government programs have been launched in many regions to address the rising incidence of kidney stones. These initiatives often include preventive measures, awareness campaigns, and efforts to improve access to advanced urolithiasis management devices. Such endeavors further contribute to the growth of the market.

The increasing prevalence of urolithiasis places a significant burden on healthcare systems globally. In response, healthcare providers are actively seeking efficient and cost-effective urolithiasis management devices to streamline patient care and reduce the economic strain associated with this condition.

Advancements in Medical Technology

Urolithiasis, commonly known as kidney stones, is a condition that affects millions of people worldwide, causing severe pain and discomfort. As the incidence of kidney stones continues to rise, so does the demand for innovative urolithiasis management devices.

Advancements in medical technology have led to the development of minimally invasive treatment options for urolithiasis. These innovations are transforming the way healthcare providers manage kidney stones. Techniques such as laser lithotripsy and advanced endoscopic tools allow for precise and less invasive methods of stone removal. Patients are increasingly seeking these treatments due to their effectiveness and the reduced discomfort and recovery times they offer.

The early and accurate diagnosis of urolithiasis is critical for timely intervention. Advanced diagnostic imaging technologies, such as high-resolution CT scans and ultrasound, have become indispensable tools for healthcare providers. These technologies not only enable quicker and more precise diagnosis but also aid in treatment planning, leading to the increased demand for urolithiasis management devices.

Advancements in medical technology have not only improved the effectiveness of urolithiasis management devices but also enhanced the overall patient experience. These devices are designed with patient comfort and safety in mind, offering less invasive procedures, reduced pain, and shorter recovery times. As a result, patients are more inclined to choose these devices for their urolithiasis management, driving the market's growth.

Robotic-assisted surgery has made significant strides in urology and has become a game-changer in the management of urolithiasis. Robots like the da Vinci Surgical System enable surgeons to perform highly precise and minimally invasive procedures with enhanced dexterity and control. This technological advancement has not only improved treatment outcomes but also increased the demand for robotic-assisted urolithiasis management devices.

The integration of telemedicine and remote patient monitoring into urology practices has further expanded the reach of urolithiasis management devices. Patients can now access consultations, follow-up care, and treatment recommendations remotely, thanks to telehealth technologies. This accessibility has made urolithiasis management more convenient and has created new opportunities for the adoption of these devices.

Rising Awareness and Education

Urolithiasis, or kidney stones, is a common urological condition that affects millions of people worldwide. As the incidence of kidney stones continues to rise, an essential factor driving the growth of the global urolithiasis management devices market is the increasing awareness and education surrounding this condition.

Increasing awareness and education about urolithiasis have contributed significantly to the growth of urolithiasis management devices. When individuals are informed about the causes, symptoms, and potential complications of kidney stones, they are more likely to seek medical attention and early diagnosis. This, in turn, creates a heightened demand for management devices as patients and healthcare providers prioritize early intervention.

Informed patients are empowered patients. As more people become educated about urolithiasis through various sources such as healthcare professionals, the internet, and patient advocacy groups, they are better equipped to make decisions regarding their healthcare. This includes choosing the most advanced and effective urolithiasis management devices available, thus contributing to the market's growth.

Awareness and education are not only about understanding the condition but also about preventing it. As people become aware of the risk factors for kidney stones, they are more likely to adopt preventive measures, such as staying well-hydrated and maintaining a healthy diet. This proactive approach can reduce the incidence of kidney stones and the need for management devices. However, when needed, these devices are seen as a crucial part of the solution.

Rising awareness and education help to remove the stigma associated with urolithiasis. When individuals openly discuss their experiences and seek information, it contributes to reducing the embarrassment often linked to this condition. Consequently, more individuals are likely to seek treatment, and healthcare providers are encouraged to employ advanced urolithiasis management devices.

The growth of urolithiasis management devices is not solely dependent on patient awareness but also on the education of healthcare providers. By staying informed about the latest advances in urolithiasis management, healthcare professionals are better equipped to recommend and utilize these devices, further promoting their adoption and use.

Patient advocacy and support groups play a vital role in raising awareness about urolithiasis. These organizations help individuals connect, share their experiences, and access valuable information. They also often collaborate with healthcare professionals and device manufacturers to drive awareness and education, ultimately increasing the demand for urolithiasis management devices.

Patient Experience and Expectations

Patients today are seeking healthcare experiences that are centered around their needs and preferences. This shift towards patient-centered care has driven the development of urolithiasis management devices that prioritize patient experience. These devices offer less invasive procedures, reduced pain, and quicker recovery times, aligning with patient expectations for comfort and convenience.

The pain associated with kidney stones is often severe and unforgettable. Patients experiencing kidney stone episodes have high expectations for minimally invasive treatments that alleviate their discomfort. Urolithiasis management devices that prioritize patient comfort by reducing pain during procedures are met with enthusiasm, contributing to the growth of the market.

Patients are no longer content with extended recovery times and downtime. Urolithiasis management devices that enable quicker recovery to have become highly sought after. Patients expect to resume their normal activities as soon as possible, and devices that offer this advantage are in high demand.

Patients anticipate safe and effective treatments with minimal complications. Urolithiasis management devices that meet these expectations not only enhance patient satisfaction but also encourage the adoption of these devices by healthcare providers and medical facilities.

Patients are increasingly looking for personalized treatment plans that cater to their unique needs. Advanced urolithiasis management devices are designed to offer tailored solutions, considering factors such as stone size and location. These devices meet the expectation for personalized care and contribute to the market's growth.

In today's tech-savvy world, patients expect healthcare solutions to be technologically advanced. Urolithiasis management devices that incorporate state-of-the-art technologies such as laser lithotripsy and robotic-assisted surgery align with patient expectations for cutting-edge treatment.


Download Free Sample Report

Key Market Challenges

High Treatment Costs

Urolithiasis management can be expensive, particularly in cases requiring surgical intervention. The cost of urolithiasis management devices, surgical procedures, hospital stays, and follow-up care can place a significant financial burden on patients. As a result, affordability remains a major concern for individuals seeking treatment and the healthcare systems that serve them.

Limited Access to Advanced Technology

Access to advanced urolithiasis management devices and technology is not uniform across all regions. Patients in underserved areas may have limited access to the latest treatment options, which can result in disparate healthcare outcomes. Bridging this access gap remains a challenge for ensuring equitable care.

Treatment Disparities

Urolithiasis management is not always consistent across different demographics. Disparities may exist in terms of access to care, the choice of management devices, and quality of treatment, resulting in uneven healthcare outcomes. Addressing these disparities is vital to ensure that all patients receive optimal care.

Key Market Trends

Innovative Urolithiasis Devices

The market is witnessing a surge in innovative urolithiasis management devices. These devices are designed to provide more precise, less invasive, and effective treatment options. Examples include high-tech lithotripters and specialized endoscopes, which allow healthcare providers to address kidney stones with increased precision.

Data-Driven Care

Data-driven approaches are increasingly influencing urolithiasis management. The collection and analysis of data related to patient outcomes, treatment efficacy, and preventive measures are guiding healthcare decisions. This data-centric approach is valuable for improving the quality of care and enhancing research and development efforts.

Patient-Centered Care

The concept of patient-centered care is growing in prominence. Patients are no longer just recipients of care but active participants in their treatment decisions. Healthcare providers are increasingly involving patients in shared decision-making, addressing their preferences and needs in the treatment process.

Segmental Insights

Treatment Type Insights

Based on the category of Treatment Type, the intracorporeal lithotripsy sector emerged as the dominant force in the market, claiming the largest portion of revenue in 2023. It is poised to exhibit the most rapid CAGR throughout the projected period. Intracorporeal lithotripsy entails the use of an endoscope to visualize stones and simultaneously disintegrate them into manageable fragments using laser technology. This method is typically employed for patients with large stones who are not suitable candidates for Extracorporeal Shock Wave Lithotripsy (ESWL). Intracorporeal lithotripsy treatments boast an impressive stone-free success rate of nearly 95% and involve minimal implantation. These procedures, performed under anesthesia, are readily accessible in medical facilities worldwide. Despite being an invasive approach, intracorporeal lithotripsy delivers remarkable stone-free outcomes, requires less time than ESWL, and is associated with minimal to no apparent side effects. Consequently, it is expected to become the preferred method for stone removal in the foreseeable future.

Conversely, in 2023, the ESWL segment secured a significant share of the revenue. ESWL remains a widely used, minimally invasive treatment due to its accessibility and cost-effectiveness. This technique primarily employs shock waves to break down stones with diameters ranging from 4 mm to 2 cm into smaller pieces, facilitating their passage from the body. Typically, ESWL is conducted on an outpatient basis, eliminating the need for a hospital stay. It is particularly effective for relatively smaller urinary stones, which are prevalent among stone-afflicted patients. The shock wave generators employed in this method include electrohydraulic, piezoelectric, and electromagnetic devices.

End Use Insights

The "Hospitals & Clinics" sector secured a substantial share of revenue in 2023, attributed to hospitals' investments in expanding their surgical infrastructure, the rise in kidney stone treatments conducted within hospital settings, and the establishment of new hospitals in various regions. Furthermore, the segment's growth is significantly influenced by the favorable reimbursement policies provided by hospitals.

On the other hand, the "Ambulatory Surgical Centers (ASCs)" category is anticipated to experience the most rapid CAGR throughout the projected period. When dealing with large obstructive urinary stones, surgical removal becomes a necessary option. Ambulatory surgical centers are gradually gaining popularity due to their time-saving and cost-effective treatment alternatives, which reduce extended hospital stays. Technological advancements in the field of surgery, including the availability of minimally invasive tools such as endoscopes and precision instruments, enable urologists to carry out painless stone removal procedures. The preference for ambulatory surgical centers for treating urinary stones is expected to be notably higher in developed countries like the United States, Canada, the United Kingdom, and Germany, primarily because of their convenient accessibility.


Download Free Sample Report

Regional Insights

In 2023, North America emerged as the dominant force in the market, capturing the largest share of revenue. This can be attributed to various factors, including the increasing incidence of stone formations leading to urolithiasis, a heightened risk of end-stage renal disease within the population, and the continual approval of new products, all of which are expected to be key drivers of market growth. According to the 2021 guidelines from the Canadian Urological Association, nephrolithiasis affects approximately 10-12% of men and 7-8% of women worldwide, with a gradual increase in urolithiasis prevalence, despite some regional variations. Furthermore, as per data from the Centers for Disease Control and Prevention (CDC), kidney disorders rank prominently among the causes of death in the United States. A significant portion of the 37 million adults with chronic kidney disease (CKD) in the U.S. remains undiagnosed. Additionally, the region is witnessing an expanding awareness among the patient population regarding the availability of new treatment options for stone-related ailments, alongside the accessibility of medical devices, further fueling market growth in North America.

Conversely, the Asia Pacific region is anticipated to experience the swiftest CAGR over the forecast period. The prevalence of kidney stones in this region is on the rise due to a combination of factors, including shifts in dietary patterns, lifestyle changes, and variations in climate. As indicated by data from the National Center for Biotechnology Information (NCBI), it is projected that the prevalence of kidney stones will reach 14.3% in China and 12.7% in India by the year 2030. Moreover, healthcare expenditure in the region is undergoing rapid expansion, driven by increased awareness among governments and individuals about the significance of good health. This is, in turn, bolstering the market, as patients are more inclined to seek treatment for kidney stones in response to these developments.

Recent Developments

  • In July 2022, Calyxo, a company specializing in technology for non-surgical kidney stone removal, announced the successful closure of its Series C investment round, raising a total of $32.7 million. This California-based company, Calyxo, developed the CVAC Aspiration system, with the objective of eliminating kidney stones without the need for surgery. This innovative system employs a combination of irrigation and aspiration techniques to achieve this.
  • In January 2022, the FDA granted breakthrough designation to Applaud Medical's Acoustic Enhancer technology, as per an official statement. San Francisco-based Applaud Medical introduced this Acoustic Enhancer technology, designed for use alongside ureteroscopy with laser lithotripsy (URS-LL) for the fragmentation of calcium-based urinary stones that cause obstruction or are deemed to pose a significant risk of future complications by urologists or other qualified medical professionals. These stones should be between 6mm and 20mm in diameter.
  • Furthermore, in March 2021, Boston Scientific and a unit of Baring Private Equity Asia (BPEA) entered into a binding agreement, with Boston Scientific agreeing to make an upfront cash payment of $1.07 billion to acquire Lumenis' global surgical business. This strategic acquisition enabled Boston Scientific to expand its global portfolio of kidney stone management products.
  • In June 2020, Olympus Corporation introduced the Soltive Laser System, a novel thulium fiber laser application specifically designed for soft tissue procedures and stone lithotripsy.

Key Market Players

  • Allengers Medical Systems Ltd
  • Boston Scientific Corp
  • Cook Medical Inc
  • CONMED Corp
  • DiREX CORP
  • Dornier MedTech GmbH
  • HealthTronics Inc
  • Karl Storz SE & Co KG
  • Lumenis Inc
  • Siemens Healthcare Ltd

 By Treatment Type

By End Use

By Region

  • Extracorporeal Shock Wave Lithotripsy (ESWL)
  • Intracorporeal Lithotripsy
  • Percutaneous Nephrolithotomy
  • Others
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Urolithiasis Management Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Urolithiasis Management Devices Market, By Treatment Type:

o   Extracorporeal Shock Wave Lithotripsy (ESWL)

o   Intracorporeal Lithotripsy

o   Percutaneous Nephrolithotomy

o   Others

  • Urolithiasis Management Devices Market, By End Use:

o   Hospitals & Clinics

o   Ambulatory Surgical Centers

o   Others

  • Urolithiasis Management Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urolithiasis Management Devices Market.

Available Customizations:

Global Urolithiasis Management Devices market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Urolithiasis Management Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Urolithiasis Management Devices Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Others)

5.2.2.    By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

5.2.3.    By Region

5.2.4.    By Company (2023)

5.3.  Market Map

5.3.1.    By Treatment Type

5.3.2.    By End Use

5.3.3.    By Region

6.    North America Urolithiasis Management Devices Market Outlook

6.1.  Market Size & Forecast       

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Others)

6.2.2.    By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

6.2.3.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Urolithiasis Management Devices Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Treatment Type

6.3.1.2.2.           By End Use

6.3.2.    Canada Urolithiasis Management Devices Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Treatment Type

6.3.2.2.2.           By End Use

6.3.3.    Mexico Urolithiasis Management Devices Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Treatment Type

6.3.3.2.2.           By End Use

7.    Europe Urolithiasis Management Devices Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Others)

7.2.2.    By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

7.2.3.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany Urolithiasis Management Devices Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Treatment Type

7.3.1.2.2.           By End Use

7.3.2.    United Kingdom Urolithiasis Management Devices Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Treatment Type

7.3.2.2.2.           By End Use

7.3.3.    France Urolithiasis Management Devices Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Treatment Type

7.3.3.2.2.           By End Use

7.3.4.    Italy Urolithiasis Management Devices Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Treatment Type

7.3.4.2.2.           By End Use

7.3.5.    Spain Urolithiasis Management Devices Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Treatment Type

7.3.5.2.2.           By End Use

8.    Asia-Pacific Urolithiasis Management Devices Market Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Others)

8.2.2.    By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

8.2.3.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Urolithiasis Management Devices Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Treatment Type

8.3.1.2.2.           By End Use

8.3.2.    Japan Urolithiasis Management Devices Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Treatment Type

8.3.2.2.2.           By End Use

8.3.3.    India Urolithiasis Management Devices Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Treatment Type

8.3.3.2.2.           By End Use

8.3.4.    Australia Urolithiasis Management Devices Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Treatment Type

8.3.4.2.2.           By End Use

8.3.5.    South Korea Urolithiasis Management Devices Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Treatment Type

8.3.5.2.2.